Global Parkinson's Disease Clinical Trials Market - Strategic Insights and Forecasts (2026-2035)

The global Parkinson’s disease clinical trials market is projected to register a strong CAGR during the forecast period from 2026 to 2035, driven by increasing investment in disease-modifying therapies, biomarker research, precision medicine, and regenerative treatment platforms.

Precision medicine is enabling targeted therapeutic development for genetically defined patient populations, including patients with LRRK2 mutations and GBA-associated Parkinson’s disease. This approach may improve treatment outcomes and increase the likelihood of clinical success.

Major market drivers include rising disease prevalence, increasing focus on disease-modifying therapies, advancements in biomarker science and genetics, growing regenerative medicine investment, and expanding global neurological research funding.

Key challenges include the complexity of disease biology, high clinical trial failure rates, long development timelines, high research costs, and the absence of universally accepted disease-modifying biomarkers and clinical endpoints.

North America remains the leading region due to strong biotechnology infrastructure, advanced academic research networks, and extensive funding availability. Europe and Asia Pacific are also major contributors to global clinical trial activity.